Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype.

TitleFamilial prion disease with Alzheimer disease-like tau pathology and clinical phenotype.
Publication TypeJournal Article
Year of Publication2011
AuthorsJayadev S, Nochlin D, Poorkaj P, Steinbart EJ, Mastrianni JA, Montine TJ, Ghetti B, Schellenberg GD, Bird TD, Leverenz JB
JournalAnn Neurol
Volume69
Issue4
Pagination712-20
Date Published2011 Apr
ISSN1531-8249
KeywordsAdult, Aged, Alzheimer Disease, Codon, Nonsense, Depressive Disorder, Major, Female, Glutamine, Humans, Memory Disorders, Memory, Short-Term, Middle Aged, Neurofibrillary Tangles, Neuropsychological Tests, Phenotype, Prion Diseases, Prion Proteins, Prions, tau Proteins, Tyrosine
Abstract

OBJECTIVE: To describe the Alzheimer disease (AD)-like clinical and pathological features, including marked neurofibrillary tangle (NFT) pathology, of a familial prion disease due to a rare nonsense mutation of the prion gene (PRNP).

METHODS: Longitudinal clinical assessments were available for the proband and her mother. After death, both underwent neuropathological evaluation. PRNP was sequenced after failure to find immunopositive Aβ deposits in the proband and the documentation of prion protein (PrP) immunopositive pathology.

RESULTS: The proband presented at age 42 years with a 3-year history of progressive short-term memory impairment and depression. Neuropsychological testing found impaired memory performance, with relatively preserved attention and construction. She was diagnosed with AD and died at age 47 years. Neuropathologic evaluation revealed extensive limbic and neocortical NFT formation and neuritic plaques consistent with a Braak stage of VI. The NFTs were immunopositive, with multiple tau antibodies, and electron microscopy revealed paired helical filaments. However, the neuritic plaques were immunonegative for Aβ, whereas immunostaining for PrP was positive. The mother of the proband had a similar presentation, including depression, and had been diagnosed clinically and pathologically as AD. Reevaluation of her brain tissue confirmed similar tau and PrP immunostaining findings. Genetic analysis revealed that both the proband and her mother had a rare PRNP mutation (Q160X) that resulted in the production of truncated PrP.

INTERPRETATION: We suggest that PRNP mutations that result in a truncation of PrP lead to a prolonged clinical course consistent with a clinical diagnosis of AD and severe AD-like NFTs.

DOI10.1002/ana.22264
Alternate JournalAnn. Neurol.
PubMed ID21416485
PubMed Central IDPMC3114566
Grant List5P50NS062684-02 / NS / NINDS NIH HHS / United States
P50 NS062684-02 / NS / NINDS NIH HHS / United States
P30 AG010133 / AG / NIA NIH HHS / United States
P50 AG005136 / AG / NIA NIH HHS / United States
R01 NS051480 / NS / NINDS NIH HHS / United States
2P50AG005136-27 / AG / NIA NIH HHS / United States
P50 NS062684 / NS / NINDS NIH HHS / United States
5R01NS051480-05 / NS / NINDS NIH HHS / United States
P50 AG005136-16 / AG / NIA NIH HHS / United States
5P30AG010133-20 / AG / NIA NIH HHS / United States